Skip to main content
. Author manuscript; available in PMC: 2018 Aug 19.
Published in final edited form as: J Neurosurg. 2012 Jun 15;117(2):227–233. doi: 10.3171/2012.5.JNS111929

TABLE 4:

Survival statistics for patients with better- and worse-prognosis melanoma brain metastasis

 Median Survival (mos)

Parameter

Overall
DS-GPA Score
0–2
DS-GPA Score
3–4

DS-GPA survival statistics*  6.7 2.73–5.42 6.83–15.64
Yale SRS w/o ipilimumab  4.9  3.03 14.67
Yale SRS w/ ipilimumab 21.3 15.67 25.2

*

As reported by Sperduto et al., 2010.